PCM
CALA

Prelude Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Prelude Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-70
Closed -$9K – 2044
2018
Q1 		$9K Buy
+70
New +$10.9K ﹤0.01% 1370
2017
Q3 		– Sell
-12
Closed -$3K – 1981
2017
Q2 		$3K Buy
+12
New +$3.21K ﹤0.01% 1511

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Prelude Capital Management's CALA Position: Q2 2018 in Review

Prelude Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2018, closing a stake of 70 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in CALA in Q2 2017 and held it in 2 quarters. The position peaked at $9K in Q1 2018. 90 funds tracked by Wall St. Rank hold CALA as of Q2 2018.

  • Prelude Capital Management reported no remaining Calithera Biosciences, Inc position as of Q2 2018 after selling out during the quarter.
  • Prelude Capital Management sold 70 Calithera Biosciences, Inc shares in Q2 2018, an estimated $9K.
  • Prelude Capital Management first reported a position in Calithera Biosciences, Inc in Q2 2017 and held it in 2 quarters.
  • Prelude Capital Management's Calithera Biosciences, Inc position peaked at $9K in Q1 2018.
  • 90 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.